ロード中...
Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
PURPOSE OF REVIEW: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. RECENT F...
保存先:
| 出版年: | Neurol Clin Pract |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669409/ https://ncbi.nlm.nih.gov/pubmed/29185542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000342 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|